NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
5 trialsNCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05536349 2026-02-24
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07363031 2026-01-23
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
Phase 2 Enrolling by invitation
NCT02768363 2025-07-30
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Candel Therapeutics, Inc.
Phase 2 Active not recruiting